<link rel="stylesheet" type="text/css" href="https://ubosquemoodle.unbosque.edu.co/theme/uebtheme/css/stylesUEB.css">
<script src="http://res.cloudinary.com/vsevolodts/raw/upload/v1503371762/timeit.min.js" type="text/javascript"></script>
<script src="http://cdnjs.cloudflare.com/ajax/libs/jquery-easing/1.3/jquery.easing.min.js" type="text/javascript"></script>
<link rel="stylesheet" href="https://ubosquemoodle.unbosque.edu.co/diseno/cursos/osteoporosis-amgen/dist/css/lightbox.min.css" />
<script src="https://ubosquemoodle.unbosque.edu.co/diseno/cursos/osteoporosis-amgen/dist/js/lightbox-plus-jquery.min.js" type="text/javascript"></script>
<script src="https://code.jquery.com/jquery-latest.min.js" type="text/javascript"></script>
<script src="http://res.cloudinary.com/vsevolodts/raw/upload/v1503371762/timeit.min.js"></script>
<script src="http://cdnjs.cloudflare.com/ajax/libs/jquery-easing/1.3/jquery.easing.min.js"></script>
<!-- ================== script ================== -->
<script src="https://code.jquery.com/jquery-latest.min.js" type="text/javascript"></script>
<!-- ================== lightbox ================== -->
<!-- ================== animate scroll ================== -->
<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/animate.css/3.5.1/animate.min.css">
<script type="text/javascript" src="https://cdnjs.cloudflare.com/ajax/libs/wow/1.1.2/wow.min.js"></script>
<!-- ================== fin animate scroll ================== -->
<!-- ================== css ================== -->
<!--<link rel="stylesheet" href="https://ubosquemoodle.unbosque.edu.co/diseno/cursos/osteoporosis-amgen/css/styles.css" />-->
<link rel="stylesheet" type="text/css" href="../../css/styles.css">
<div class="curso-cc">
  <div class="container-fluid">
    <div class="row-fluid">
      <article class="content-cc article">
        <div id="menu"></div>
        <div class="banner-videos">
          <div id="banner-mod-5"></div>
          <div class="title-bg"></div>
          <div class="title">
            <div>Diplomado Virtual</div>
            <div>Osteoporosis</div>
          </div>
        </div>
        <h2>Módulo 5 / <span>Tratamiento farmacológico combinado, secuencial y Adherencia terapéutica</span></h2>
        <h3>10. Bibliografía</h3>
        <ol>
          <li>Binkley, N., & Krueger, D. (2005). Combination therapy for osteoporosis: Considerations and controversy. Current Osteoporosis Reports, 3(4), 150–154. doi:10.1007/s11914-996-0018-1 </li>
          <li>Black, D. M., Greenspan, S. L., Ensrud, K. E., Palermo, L., McGowan, J. A., Lang, T. F., . . . PaTH Study Investigators. (2003). The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. The New England Journal of Medicine, 349(13), 1207-1215. doi:10.1056/NEJMoa031975</li>
          <li>Black, D. M., Bilezikian, J. P., Ensrud, K. E., Greenspan, S. L., Palermo, L., Hue, T., … Rosen, C. J. (2005). One Year of Alendronate after One Year of Parathyroid Hormone (1–84) for Osteoporosis. New England Journal of Medicine, 353(6), 555–565.doi:10.1056/nejmoa050336</li>
          <li>Bone, H. G., Cosman, F., Miller, P. D., Williams, G. C., Hattersley, G., Hu, M., … Saag, K. G. (2018). ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. The Journal of Clinical Endocrinology & Metabolism, 103(8), 2949–2957.doi:10.1210/jc.2018-00163 </li>
          <li>Bonanni, S., Sorensen, A. A., Dubin, J., & Drees, B. (2017, Jul). The role of the fracture liaison service in osteoporosis care. Missouri Medicine, 114, 295. Retrieved from  <a href="https://www.ncbi.nlm.nih.gov/pubmed/30228614" target="_blank">https://www.ncbi.nlm.nih.gov/pubmed/30228614  </a></li>
          <li>Boonen, S., Marin, F., Obermayer-Pietsch, B., Simões, M. E., Barker, C., Glass, E. V., . . . McCloskey, E. V. (2008). Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. The Journal of Clinical Endocrinology and Metabolism, 93(3), 852-860. doi:10.1210/jc.2007-0711</li>
          <li>Boudreau, D. M., Yu, O., Balasubramanian, A., Wirtz, H., Grauer, A., Crittenden, D. B., & Scholes, D. (2017). A survey of women's awareness of and reasons for lack of postfracture osteoporotic care. Journal of the American Geriatrics Society, 65(8), 1829-1835. doi:10.1111/jgs.14921</li>
          <li>Camacho, P. M., Petak, S. M., Binkley, N., Clarke, B. L., Harris, S. T., Hurley, D. L., . . . Watts, N. B. (2016). American association of clinical endocrinologists and american college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis - 2016--executive summary. Endocrine Practice: Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 22(9), 1111-1118. doi:10.4158/EP161435.ESGL</li>
          <li>Caro, J. J., Ishak, K. J., Huybrechts, K. F., Raggio, G., & Naujoks, C. (2004). The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporosis International, 15(12), 1003–1008.doi:10.1007/s00198-004-1652-z </li>
          <li>Clowes, J. A., Peel, N. F. A., & Eastell, R. (2004). The Impact of Monitoring on Adherence and Persistence with Antiresorptive Treatment for Postmenopausal Osteoporosis: A Randomized Controlled Trial. The Journal of Clinical Endocrinology & Metabolism, 89(3), 1117–1123.doi:10.1210/jc.2003-030501 </li>
          <li>Compston, J. E., & Seeman, E. (2006). Compliance with osteoporosis therapy is the weakest link. The Lancet, 368(9540), 973–974.</li>
          <li>Cons Molina, Francisco. (2019). Retrospective-prospective Observational Study in rEal life treatment in LatinAmerican patients with denosumb query database (ROSELA Data Base), presentación en Bone Academy. Puerto Vallarta México</li>
          <li>Cosman, F., Nieves, J., Woelfert, L., Formica, C., Gordon, S., Shen, V., & Lindsay, R. (2001). Parathyroid Hormone Added to Established Hormone Therapy: Effects on Vertebral Fracture and Maintenance of Bone Mass After Parathyroid Hormone Withdrawal. Journal of Bone and Mineral Research, 16(5), 925–931</li>
          <li>Cosman, F., de Beur, S., LeBoff, M., Lewiecki, E., Tanner, B., Randall, S., & Lindsay, R. (2014). Clinician’s guide to prevention and treatment of osteoporosis. Osteoporosis International, 25(10), 2359-2381. doi:10.1007/s00198-014-2794-2</li>
          <li>Cramer, J., Gold, D., Silverman, S., & Lewiecki, E. (2007). A systematic review of persistence and compliance with bisphosphonates for osteoporosis.Osteoporosis International, 18(8), 1023-1031. doi:10.1007/s00198-006-0322-8</li>
          <li>Cramer, J. A., Roy, A., Burrell, A., Fairchild, C. J., Fuldeore, M. J., Ollendorf, D. A., & Wong, P. K. (2008). Medication compliance and persistence: Terminology and definitions. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 11(1), 44-47. doi:10.1111/j.1524-4733.2007.00213.x</li>
          <li>Cummings, S. R., & Melton, L. J. (2002). Epidemiology and outcomes of osteoporotic fractures. Lancet (London, England), 359(9319), 1761-1767. doi:10.1016/S0140-6736(02)08657-9</li>
          <li>Diez-Perez, A., Naylor, K. E., Abrahamsen, B., Agnusdei, D., Brandi, M. L., Cooper, C., . . . Eastell, R. (2017). International osteoporosis foundation and european calcified tissue society working group. recommendations for the screening of adherence to oral bisphosphonates. Osteoporosis International: A Journal Established as Result of Cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 28(3), 767-774. doi:10.1007/s00198-017-3906-6</li>
          <li>Dilla, T., Valladares, A., Lizán, L., & Sacristán, J. A. (2009). Adherencia y persistencia terapéutica: Causas, consecuencias y estrategias de mejora.Atención Primaria, 41(6), 342-348. doi:10.1016/j.aprim.2008.09.031</li>
          <li>Eliasaf, A., Amitai, A., Maram Edry, M., Yosselson Superstine, S., & Rotman Pikielny, P. (2016). Compliance, persistence, and preferences regarding osteoporosis treatment during active therapy or drug holiday. Journal of Clinical Pharmacology, 56(11), 1416-1422. doi:10.1002/jcph.738</li>
          <li>Emkey, R., Delmas, P. D., Bolognese, M., Borges, J. L. C., Cosman, F., Ragi-Eis, S., … Epstein, S. (2009). Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): Additional results from the monthly oral therapy with ibandronate for osteoporosis intervention (MOTION) study. Clinical Therapeutics, 31(4), 751–761.doi:10.1016/j.clinthera.2009.04.018 </li>
          <li>Eastell, R., Nickelsen, T., Marin, F., Barker, C., Hadji, P., Farrerons, J., … Glüer, C. C. (2009). Sequential Treatment of Severe Postmenopausal Osteoporosis After Teriparatide: Final Results of the Randomized, Controlled European Study of Forsteo (EUROFORS)*. Journal of Bone and Mineral Research, 24(4), 726–736.doi:10.1359/jbmr.081215 </li>
          <li>Fahrleitner-Pammer, A., Papaioannou, N., Gielen, E., Feudjo Tepie, M., Toffis, C., Frieling, I., . . . Hadji, P. (2017). Factors associated with high 24-month persistence with denosumab: Results of a real-world, non-interventional study of women with postmenopausal osteoporosis in germany, austria, greece, and belgium. Archives of Osteoporosis, 12(1), 58. doi:10.1007/s11657-017-0351-2</li>
          <li>Finkelstein, J. S., Hayes, A., Hunzelman, J. L., Wyland, J. J., Lee, H., & Neer, R. M. (2003). The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis. New England Journal of Medicine, 349(13), 1216–1226</li>
          <li>Foster, S. A., Foley, K. A., Meadows, E. S., Johnston, J. A., Wang, S. S., Pohl, G. M., & Long, S. R. (2011a). Adherence and persistence with teriparatide among patients with commercial, medicare, and medicaid insurance. Osteoporosis International: A Journal Established as Result of Cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 22(2), 551-557. doi:10.1007/s00198-010-1297-z</li>
          <li>Freemantle, N., Satram-Hoang, S., Tang, E. -., Kaur, P., Macarios, D., Siddhanti, S., . . . Kendler, D. L. (2012). Final results of the DAPS (denosumab adherence preference satisfaction) study: A 24-month, randomized, crossover comparison with alendronate in postmenopausal women.Osteoporosis International: A Journal Established as Result of Cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 23(1), 317-326. doi:10.1007/s00198-011-1780-1</li>
          <li>Gold, D. T., & Silverman, S. (2006). Review of adherence to medications for the treatment of osteoporosis. Current Osteoporosis Reports, 4(1), 21–27. doi:10.1007/s11914-006-0011-8 </li>
          <li>González-Macías, J., del Pino-Montes, J., Olmos, J. M., & Nogués, X. (2015). Guías de práctica clínica en la osteoporosis posmenopáusica, glucocorticoidea y del varón. sociedad española de investigación ósea y del metabolismo mineral (3.ª versión actualizada 2014). Revista Clínica Española, 215(9), 515-526. doi:10.1016/j.rce.2015.08.003</li>
          <li>Grant, A. M., Avenell, A., Campbell, M. K., McDonald, A. M., MacLennan, G. S., McPherson, G. C., . . . Wallace, W. A. (2005). Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (randomised evaluation of calcium or vitamin D, RECORD): A randomised placebo-controlled trial. Lancet (London, England), 365(9471), 1621-1628. doi:10.1016/S0140-6736(05)63013-9</li>
          <li>Hadji, P., Papaioannou, N., Gielen, E., Feudjo Tepie, M., Zhang, E., Frieling, I., . . . Fahrleitner-Pammer, A. (2015). Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in germany, austria, greece, and belgium: 12-month results from a european non-interventional study. Osteoporosis International: A Journal Established as Result of Cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 26(10), 2479-2489. doi:10.1007/s00198-015-3164-4</li>
          <li>Harris, S. T., Eriksen, E. F., Davidson, M., Ettinger, M. P., Moffett, A. H., Baylink, D. J., . . . Chines, A. A. (2001). Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. The Journal of Clinical Endocrinology and Metabolism, 86(5), 1890-1897. doi:10.1210/jcem.86.5.7505</li>
          <li>Hiligsmann, M., Salas, M., Hughes, D. A., Manias, E., Gwadry-Sridhar, F. H., Linck, P., & Cowell, W. (2013). Interventions to improve osteoporosis medication adherence and persistence: A systematic review and literature appraisal by the ISPOR medication adherence & persistence special interest group. Osteoporosis International: A Journal Established as Result of Cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 24(12), 2907-2918. doi:10.1007/s00198-013-2364-z</li>
          <li>Hudson, B., Toop, L., Mangin, D., & Pearson, J. (2011). Risk communication methods in hip fracture prevention: a randomised trial in primary care. British Journal of General Practice, 61(589), e469–e476. doi:10.3399/bjgp11x588439</li>
          <li>Huybrechts, K. F., Ishak, K. J., & Caro, J. J. (2006). Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone, 38(6), 922-928. doi:10.1016/j.bone.2005.10.022</li>
          <li>Inderjeeth, C. A., Inderjeeth, A., & Raymond, W. D. (2016). Medication selection and patient compliance in the clinical management of osteoporosis.Australian Family Physician, 45(11), 814-817. Retrieved from   <a href="https://search.informit.com.au/documentSummary;dn=429358000928299;res=IELHEA" target="_blank">https://search.informit.com.au/documentSummary;dn=429358000928299;res=IELHEA</a></li>
          <li>Jackson, R. D., LaCroix, A. Z., Gass, M., Wallace, R. B., Robbins, J., Lewis, C. E., . . . Barad, D. (2006). Calcium plus vitamin D supplementation and the risk of fractures. New England Journal of Medicine, 354(7), 669-683. doi:10.1056/NEJMoa055218</li>
          <li>Johnell, O., Scheele, W. H., Lu, Y., Reginster, J., Need, A. G., & Seeman, E. (2002). Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. The Journal of Clinical Endocrinology & Metabolism, 87(3), 985-992. doi:10.1210/jcem.87.3.8325</li>
          <li>Kyvernitakis, I., Kostev, K., Kurth, A., Albert, U. S., & Hadji, P. (2014). Differences in persistency with teriparatide in patients with osteoporosis according to gender and health care provider. Osteoporosis International: A Journal Established as Result of Cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 25(12), 2721-2728. doi:10.1007/s00198-014-2810-6</li>
          <li>Kothawala, P., Badamgarav, E., Ryu, S., Miller, R. M., & Halbert, R. J. (2007). Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clinic Proceedings, 82(12), 1493-1501. doi:10.1016/S0025-6196(11)61093-8</li>
          <li>Lagari, V. S., McAninch, E., & Baim, S. (2015). Considerations regarding adherence of anti-osteoporosis therapy. Postgraduate Medicine, 127(1), 92-98. doi:10.1080/00325481.2015.993278</li>
          <li>Leder, B. Z., Tsai, J. N., Uihlein, A. V., Wallace, P. M., Lee, H., Neer, R. M., & Burnett-Bowie, S.-A. M. (2015). Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. The Lancet, 386(9999), 1147–1155. doi:10.1016/s0140-6736(15)61120-5 </li>
          <li>Leder, B. Z. (2018). Optimizing sequential and combined anabolic and antiresorptive osteoporosis therapy. JBMR Plus, 2(2), 62-68. doi:10.1002/jbm4.10041</li>
          <li>Lindsay, R., Cosman, F., Lobo, R. A., Walsh, B. W., Harris, S. T., Reagan, J. E., . . . Byrnes, C. A. (1999). Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: A randomized, controlled clinical trial. The Journal of Clinical Endocrinology & Metabolism, 84(9), 3076-3081. doi:10.1210/jcem.84.9.5989</li>
          <li>Lindsay, B. R., Olufade, T., Bauer, J., Babrowicz, J., & Hahn, R. (2016). Patient-reported barriers to osteoporosis therapy. Archives of Osteoporosis, 11(1).doi:10.1007/s11657-016-0272-5 </li>
          <li>Lorentzon, M. (2019). Treating osteoporosis to prevent fractures: current concepts and future developments. Journal of Internal Medicine. doi:10.1111/joim.12873 </li>
          <li>Lou, S., Wang, L., Wang, Y., Jiang, Y., Liu, J., & Wang, Y. (2017). Combination therapy of anabolic and nonbisphosphonates antiresorptive agents for the treatment of osteoporosis. Medicine, 96(52), e9534.doi:10.1097/md.0000000000009534 </li>
          <li>Martin, T. J. (2006). Mechanisms Involved in Skeletal Anabolic Therapies. Annals of the New York Academy of Sciences, 1068(1), 458–470. doi:10.1196/annals.1346.043 </li>
          <li>McClung, M. R., Grauer, A., Boonen, S., Bolognese, M. A., Brown, J. P., Diez-Perez, A., … Bone, H. G. (2014). Romosozumab in Postmenopausal Women with Low Bone Mineral Density. New England Journal of Medicine, 370(5), 412–420.doi:10.1056/nejmoa1305224 </li>
          <li>McCombs, J. S., Thiebaud, P., McLaughlin-Miley, C., & Shi, J. (2004). Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas, 48(3), 271–287.doi:10.1016/j.maturitas.2004.02.005 </li>
          <li>Medina Orjuela, A., Rosero Olarte, Ó., Nel Rueda Plata, P., Sánchez Escobar, F., Chalem Choueka, M., González Reyes, M. Á., … Londoño Gutiérrez, R. (2018). II Consenso Colombiano para el Manejo de la Osteoporosis Posmenopáusica. Revista Colombiana de Reumatología. doi:10.1016/j.rcreu.2018.02.006</li>
          <li>Miller, P. D. (2007). Monitoring osteoporosis therapies. Current Osteoporosis Reports, 5(1), 38–43.</li>
          <li>Miller, P. D., Delmas, P. D., Lindsay, R., Watts, N. B., Luckey, M., Adachi, J., . . . Bilezikian, J. P. (2008). Early responsiveness of women with osteoporosis to teriparatide after therapy</li>
          <li>with alendronate or risedronate. The Journal of Clinical Endocrinology and Metabolism, 93(10), 3785-3793. doi:10.1210/jc.2008-0353</li>
          <li>Modi, A., Sen, S., Adachi, J. D., Adami, S., Cortet, B., Cooper, A. L., . . . Sajjan, S. (2016). Gastrointestinal symptoms and association with medication use patterns, adherence, treatment satisfaction, quality of life, and resource use in osteoporosis: Baseline results of the MUSIC-OS study. Osteoporosis International, 27(3), 1227-1238.</li>
          <li>Modi, A., Sajjan, S., Insinga, R., Weaver, J., Lewiecki, E. M., & Harris, S. T. (2017). Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years. Osteoporosis International: A Journal Established as Result of Cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 28(4), 1355-1363. doi:10.1007/s00198-016-3886-y</li>
          <li>Morfeld, J., Vennedey, V., Müller, D., Pieper, D., & Stock, S. (2017). Patient education in osteoporosis prevention: A systematic review focusing on methodological quality of randomised controlled trials. Osteoporosis International: A Journal Established as Result of Cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 28(6), 1779-1803. doi:10.1007/s00198-017-3946-y</li>
          <li>National Osteoporosis Foundation. (2016).  Bone Health Index Survey. www.nof.org</li>
          <li>Naylor, K. E., Jacques, R. M., Paggiosi, M., Gossiel, F., Peel, N. F. A., McCloskey, E. V., … Eastell, R. (2015). Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study. Osteoporosis International, 27(1), 21–31. doi:10.1007/s00198-015-3145-7</li>
          <li>Qaseem, A., Forciea, M. A., McLean, R. M., & Denberg, T. D. (2017). Treatment of low bone density or osteoporosis to prevent fractures in men and women: A clinical practice guideline update from the american college of physicians. Annals of Internal Medicine, 166(11), 818-839. doi:10.7326/M15-1361</li>
          <li>Rittmaster, R. S., Bolognese, M., Ettinger, M. P., Hanley, D. A., Hodsman, A. B., Kendler, D. L., & Rosen, C. J. (2000). Enhancement of Bone Mass in Osteoporotic Women with Parathyroid Hormone followed by Alendronate1. The Journal of Clinical Endocrinology & Metabolism, 85(6), 2129–2134.doi:10.1210/jcem.85.6.6614 </li>
          <li>Rosen, C. J., Hochberg, M. C., Bonnick, S. L., McClung, M., Miller, P., Broy, S., … de Papp, A. E. (2004). Treatment With Once-Weekly Alendronate 70 mg Compared With Once-Weekly Risedronate 35 mg in Women With Postmenopausal Osteoporosis: A Randomized Double-Blind Study. Journal of Bone and Mineral Research, 20(1), 141–151.doi:10.1359/jbmr.040920</li>
          <li>Rosenblatt, M. (2003). Is It Ethical to Conduct Placebo-Controlled Clinical Trials in the Development of New Agents for Osteoporosis? An Industry Perspective. Journal of Bone and Mineral Research, 18(6), 1142–1145.</li>
          <li>Rossini, M., Bianchi, G., Di Munno, O., Giannini, S., Minisola, S., Sinigaglia, L., & Adami, S. (2006). Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporosis International: A Journal Established as Result of Cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 17(6), 914-921. doi:10.1007/s00198-006-0073-6</li>
          <li>Saag, K. G., Petersen, J., Brandi, M. L., Karaplis, A. C., Lorentzon, M., Thomas, T., … Grauer, A. (2017). Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. New England Journal of Medicine, 377(15), 1417–1427.doi:10.1056/nejmoa1708322 </li>
          <li>Sakuma, S., Tanno, F. K., Masaoka, Y., Kataoka, M., Kozaki, T., Kamaguchi, R., . . . Yamashita, S. (2007). Effect of administration site in the gastrointestinal tract on bioavailability of poorly absorbed drugs taken after a meal. Journal of Controlled Release: Official Journal of the Controlled Release Society, 118(1), 59-64. doi:10.1016/j.jconrel.2006.12.016</li>
          <li>Sikka, R., Xia, F., & Aubert, R. E. (2005). Estimating medication persistency using administrative claims data. The American Journal of Managed Care, 11(7), 449-457.</li>
          <li>Silverman, S., Siris, E., Belazi, D., Recknor, C., Papaioannou, A., Brown, J., . . . Kendler, D. (2018). Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: Results of a prospective cohort study. Archives of Osteoporosis, 13(1), 1-10. doi:10.1007/s11657-018-0491-z</li>
          <li>Siris, E. S., Harris, S. T., Rosen, C. J., Barr, C. E., Arvesen, J. N., Abbott, T. A., & Silverman, S. (2006). Adherence to Bisphosphonate Therapy and Fracture Rates in Osteoporotic Women: Relationship to Vertebral and Nonvertebral Fractures From 2 US Claims Databases. Mayo Clinic Proceedings, 81(8), 1013–1022.doi:10.4065/81.8.1013 </li>
          <li>Siris, E. S., Selby, P. L., Saag, K. G., Borgström, F., Herings, R. M. C., & Silverman, S. L. (2009). Impact of Osteoporosis Treatment Adherence on Fracture Rates in North America and Europe. The American Journal of Medicine, 122(2), S3–S13.doi:10.1016/j.amjmed.2008.12.002</li>
          <li>Stuurman-Bieze, A. G. G., Hiddink, E. G., van Boven, J. F. M., & Vegter, S. (2014). Proactive pharmaceutical care interventions decrease patients' nonadherence to osteoporosis medication. Osteoporosis International: A Journal Established as Result of Cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 25(6), 1807-1812. doi:10.1007/s00198-014-2659-8</li>
          <li>Trevena, L. J., Barratt, A., Butow, P., & Caldwell, P. (2006). A systematic review on communicating with patients about evidence. Journal of Evaluation in Clinical Practice, 12(1), 13–23.doi:10.1111/j.1365-2753.2005.00596.x</li>
          <li>Tsai, J. N., Uihlein, A. V., Lee, H., Kumbhani, R., Siwila-Sackman, E., McKay, E. A., … Leder, B. Z. (2013). Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. The Lancet, 382(9886), 50–56.doi:10.1016/s0140-6736(13)60856-9   </li>
          <li>Walters, S., Khan, T., Ong, T., & Sahota, O. (2017). Fracture liaison services: improving outcomes for patients with osteoporosis. Clinical Interventions in Aging, Volume 12, 117–127. doi:10.2147/cia.s85551 </li>
          <li>Woo, C., Gao, G., Wade, S., & Hochberg, M. C. (2010). Gastrointestinal side effects in postmenopausal women using osteoporosis therapy: 1-year findings in the POSSIBLE US study. Current Medical Research and Opinion, 26(4), 1003-1009. doi:10.1185/03007991003633603</li>
          <li>Yood, R. A., Emani, S., Reed, J. I., Lewis, B. E., Charpentier, M., & Lydick, E. (2003). Compliance with pharmacologic therapy for osteoporosis. Osteoporosis International, 14(12), 965–968.doi:10.1007/s00198-003-1502-4</li>
        </ol>
        <div class="container-fluid">
          <div class="row-fluid wow fadeInUp material-modulo">
            <div id="material-mod-5"></div>
          </div>
        </div>
        <div class="container-fluid">
          <div class="row-fluid">
            <div class="span" id="footer-2"></div>
          </div>
        </div>
        <div class="progress-fullbar">
          <div class="pager">
            <div class="paginas">
              <ul>
                <li class="previous"><a class="back" href="https://ubosquemoodle.unbosque.edu.co/mod/book/view.php?id=300080&amp;chapterid=8960"><i class="fa fa-angle-left" aria-hidden="true"></i>&nbsp;<span>Anterior</span></a></li>
                <li class="next"><a class="disabled" href="#"><span>Siguiente</span>&nbsp;<i class="fa fa-angle-right" aria-hidden="true"></i></a></li>
              </ul>
            </div>
            <div class="counter"><p><span class="eta"></span> (<!--<span class="words"></span>--> &cong; Tiempo de lectura )</p></div>
            <div class="menuanchorbot"><a class="btn-primary" href="#menuanchor-top">Menú</a></div>
          </div>
          <div class="progressContainer">
            <div class="progress" id="progress"></div>
          </div>
        </div>
      </article>
    </div>
  </div>
</div><!-- ================== script ================== -->
<script src="../../Menu/menu.js" type="text/javascript"></script>
<script src="../../Menu/timeit.js"></script>
<script src="../../Menu/scrollbar.js"></script>
<!-- ================== fin script ================== -->
<script src="//ajax.googleapis.com/ajax/libs/jquery/1.9.0/jquery.min.js"></script>
<script>
  if (typeof jQuery == 'undefined') {
  	document.write(unescape("%3Cscript src='../src/lib/jquery.1.9.1.min.js' type='text/javascript'%3E%3C/script%3E"));
  }
  
</script>
<script>
  $(function() {
  
  	$('article').each(function() {
  
  		const _this = $(this);
  
  		_this.readingTime({
  			readingTimeTarget: _this.find('.eta'),
  			wordCountTarget: _this.find('.words'),
  			success: function(data) {
  				console.log(data);
  			},
  			error: function(data) {
  				_this.find('.eta').remove();
  			}
  		});
  	});
  });
  
</script><script src="../../Menu/readingtime.js"></script>
<script type="text/javascript">$(document).ready(function() {$("#single_1").fancybox({helpers: {title : {type : 'float'}}	});});</script>
<script type="text/javascript">$(".menu-toggle").click(function() {$("nav > ul").slideToggle( "700");$("nav > ul").css('display','flex');});</script>
<script>
  $('#scrollup').click(function(){
  	$(".menuanchor-top").animate({ scrollTop: 0 }, 400);
  	return false;
  });
  
  
  
  
  
  
  
</script><!-- ================== script animate scroll ================== -->
<script type="text/javascript">new WOW().init();</script>
<!-- ================== fin script animate scroll ================== -->
<!-- <script src="http://code.jquery.com/jquery.js"></script> -->
<script src="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/2.3.2/js/bootstrap.min.js"></script>